CpG(B)-STAT3dODN efficacy was also superior when compared to that of atovaquone, a recently described STAT3 inhibitor with activity against human multiple myeloma and acute myeloid leukemia (AML) (Figure S6).42 Here, STAT3 is linked to AL amyloidosis.